 | Immunisation body likely to consider Corbevax as booster for those jabbed with Covishield, CovaxinThe Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. |
 | DCGI to review Serum Institute's applications for Covovax use in kids aged 2 to 7 yrs, 7 to 11 yrsThe expert panel in its last meeting in April had sought more data from SII following its application seeking the emergency use authorization of Covovax for seven to 11 years. |
 | ‘Covaxin booster improves efficacy against two variants’: Bharat BiotechA booster dose of Covaxin enhances vaccine effectiveness against Delta and Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech said. |
 | Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, find ICMR studyThe findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer reviewed. |
 | NTAGI to discuss allowing Corbevax as booster for those vaccinated with Covishield, Covaxin: SourcesThe Drugs Controller General of India (DCGI) on Sunday approved Corbevax for the precaution dose for those aged 18 and above. |
 | Germany to recognise Covaxin for travel purpose from June 1, says envoyIn November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin. |
 | FDA lifts hold on Covaxin's clinical trials in USThe FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab. |
 | Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-oldPresently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose. |
 | Bharat Biotech's Covaxin gets emergency approval for 6-12 age groupThe company said it conducted clinical trials in the paediatric population between June 2021 to September 2021 and results have shown robust safety, reactogenicity, and immunogenicity. |
 | Covid-19: Three vaccines for children get emergency use approval from drug controllerThe new approvals were tweeted by Union Health Minister Dr Mansukh Mandaviya, who said that India's fight against Covid has become more robust. |
 | Ocugen to commercialise Covaxin in MexicoCity-based pharma major Bharat Biotech’s US partner Ocugen, Inc. has got the permission to commercialise Covid vaccine Covaxin in Mexico. |
 | Bharat Biotech expands Covaxin pact with Ocugen to enter North America marketThe Hyderabad-based pharma major has also sought EUA for use of Covaxin for children in the 2-18 years age group in Mexico. |
 | Covaxin's phase 2/3 clinical trials put on hold in the USThe WHO had earlier suspended supply through UN agencies of Coavaxin after inspectors identified good manufacturing practice deficiencies in the company's pharma plant. |
 | US FDA puts Covaxin's second phase trials in US on hold after fallout on WHO's observationsWHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP deficiencies in the Bharat Biotech's manufacturing plants. |
 | Covishield & Covaxin prices cut, hospitals to pay Rs 225 per doseThe precautionary dose has to be of the same vaccine used for the first two doses. |
